Specific HLA alleles, paired with TCR V- and J-gene segment usage, link to distinct multiple myeloma survival rates

References

• Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017;31(9):1915–1921.
   PubMed Web of Science ®Google Scholar
• Ozer H, Han T, Henderson ES, et al. Immunoregulatory T cell function in multiple myeloma. J Clin Invest. 1981;67(3):779–789.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Raje N, Fowler JA, et al. How to train your t cells: overcoming immune dysfunction in multiple myeloma. Clin Cancer Res. 2020;26(7):1541–1554.
   PubMed Web of Science ®Google Scholar
• Cohen AD. Myeloma: next generation immunotherapy. Hematology Am Soc Hematol Educ Program. 2019;2019(1):266–272.
   PubMedGoogle Scholar
• Manasanch EE, Han G, Mathur R, et al. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019;3(15):2400–2408.
   PubMed Web of Science ®Google Scholar
• Sun J, Muz B, Alhallak K, et al. Targeting CD47 as a novel immunotherapy for multiple myeloma. Cancers. 2020;12(2):305.
   Web of Science ®Google Scholar
• Jindal V, Khoury J, Gupta R, et al. Current status of chimeric antigen receptor T-cell therapy in multiple myeloma. Am J Clin Oncol. 2020;43(5):371–377.
   PubMed Web of Science ®Google Scholar
• Perez-Amill L, Sune G, Antonana-Vildosola A, et al. Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. haematol. 2020;106(1):173–184.
   Web of Science ®Google Scholar
• Freyer CW, Porter DL. Advances in CAR T therapy for hematologic malignancies. Pharmacotherapy. 2020;40(8):741–755.
   PubMed Web of Science ®Google Scholar
• Perumal D, Imai N, Lagana A, et al. Mutation-derived neoantigen-specific T-cell responses in multiple myeloma. Clin Cancer Res. 2020;26(2):450–464.
   PubMed Web of Science ®Google Scholar
• Perez C, Botta C, Zabaleta A, et al. Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma. Blood. 2020;136(2):199–209.
   PubMed Web of Science ®Google Scholar
• Sant S, Jenkins MR, Dash P, et al. Human γδ T-cell receptor repertoire is shaped by influenza viruses, age and tissue compartmentalisation . Clin Transl Immunology. 2019;8(9):e1079.
   PubMed Web of Science ®Google Scholar
• Li Y, Ma L, Dong X, et al. Preliminary analysis of spatial-temporal homogeneity and heterogeneity of TCR beta chain CDR3 repertoires in BALB/c mice. Int J Mol Epidemiol Genet. 2019;10(1):10–28.
   PubMed Web of Science ®Google Scholar
• Salminen A, Kaarniranta K, Kauppinen A. Immunosenescence: the potential role of myeloid-derived suppressor cells (MDSC) in age-related immune deficiency. Cell Mol Life Sci. 2019;76(10):1901–1918.
   PubMed Web of Science ®Google Scholar
• Roca AM, Chobrutskiy BI, Callahan BM, et al. T-cell receptor V and J usage paired with specific HLA alleles associates with distinct cervical cancer survival rates. Hum Immunol. 2019;80(4):237–242.
   PubMed Web of Science ®Google Scholar
• Klarenbeek PL, Doorenspleet ME, Esveldt RE, et al. Somatic variation of T-cell receptor genes strongly associate with HLA class restriction. PloS One. 2015;10(10):e0140815.
   PubMed Web of Science ®Google Scholar
• Cui JH, Jin YB, Lin KR, et al. Characterization of peripheral blood TCR repertoire in patients with ankylosing spondylitis by high-throughput sequencing. Hum Immunol. 2018;79(6):485–490.
   PubMed Web of Science ®Google Scholar
• Zeng G, Huang Y, Huang Y, et al. Antigen-specificity of T cell infiltrates in biopsies with T cell-mediated rejection and BK polyomavirus viremia: analysis by next generation sequencing. Am J Transplant. 2016;16(11):3131–3138.
   PubMed Web of Science ®Google Scholar
• Di Sante G, Tolusso B, Fedele AL, et al. Collagen specific T-cell repertoire and HLA-DR alleles: biomarkers of active refractory rheumatoid arthritis. EBioMedicine. 2015;2(12):2037–2045.
   PubMed Web of Science ®Google Scholar
• Infante AJ, Levcovitz H, Gordon V, et al. Preferential use of a T cell receptor V beta gene by acetylcholine receptor reactive T cells from myasthenia gravis-susceptible mice. J Immunol. 1992;148(11):3385–3390.
   PubMed Web of Science ®Google Scholar
• Packiriswamy N, Upreti D, Zhou Y, et al. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. Leukemia. 2020;34(12):3310–3322.
   PubMed Web of Science ®Google Scholar
• Muller LME, Holmes M, Michael JL, et al. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. J Immunother Cancer. 2019;7(1):164.
   PubMedGoogle Scholar
• Miller A, Asmann Y, Cattaneo L, et al. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. Blood Cancer J. 2017;7(9):e612.
   PubMedGoogle Scholar
• Xie C, Yeo ZX, Wong M, et al. Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. Proc Natl Acad Sci U S A. 2017;114(30):8059–8064.
   PubMed Web of Science ®Google Scholar
• Gill TR, Samy MD, Butler SN, et al. Detection of productively rearranged TcR-alpha V-J sequences in TCGA Exome files: implications for tumor immunoscoring and recovery of antitumor T-cells. Cancer Inform. 2016;15:23–28.
   PubMed Web of Science ®Google Scholar
• Chobrutskiy BI, Zaman S, Tong WL, et al. Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade. J Neurooncol. 2018;140(3):697–704.
   PubMed Web of Science ®Google Scholar
• Tong WL, Tu YN, Samy MD, et al. Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: evidence for high level B-cell infiltrates in breast cancer. Hum Vaccin Immunother. 2017;13(3):501–506.
   PubMed Web of Science ®Google Scholar
• Safaeian M, Johnson LG, Yu K, et al. Human leukocyte antigen class I and II alleles and cervical adenocarcinoma. Front Oncol. 2014;4:119.
   PubMedGoogle Scholar
• Kiewe P, Mansmann V, Scheibenbogen C, et al. HLA-A2 expression, stage, and survival in colorectal cancer. Int J Colorectal Dis. 2008;23(8):767–772.
   PubMed Web of Science ®Google Scholar
• Ishigami S, Arigami T, Okumura H, et al. Human leukocyte antigen (HLA)-E and HLA-F expression in gastric cancer. Anticancer Res. 2015;35(4):2279–2285.
   PubMed Web of Science ®Google Scholar
• Callahan BM, Tong WL, Blanck G. T cell receptor-beta J usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates. Immunol Res. 2018;66(2):219–223.
   PubMed Web of Science ®Google Scholar
• Callahan BM, Yavorski JM, Tu YN, et al. T-cell receptor-beta V and J usage, in combination with particular HLA class I and class II alleles, correlates with cancer survival patterns. Cancer Immunol Immunother. 2018;67(6):885–892.
   PubMed Web of Science ®Google Scholar
• Tong WL, Callahan BM, Tu YN, et al. Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates. Breast Cancer Res Treat. 2019;173(1):167–177.
   PubMed Web of Science ®Google Scholar
• Clark KR, Tong WL, Callahan BM, et al. TRB-J1 usage, in combination with the HLA-A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates. Int J Immunogenet. 2019;46(1):31–37.
   PubMed Web of Science ®Google Scholar
• Beksac M, Gragert L, Fingerson S, et al. HLA polymorphism and risk of multiple myeloma. Leukemia. 2016;30(11):2260–2264.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou X, Zhu JW, et al. Association of CD117 and HLA-DR expression with shorter overall survival and/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation. Oncol Lett. 2018;16(5):5655–5666.
   PubMed Web of Science ®Google Scholar
• Yavorski JM, Blanck G. MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development. Mol Clin Oncol. 2017;7(6):1119–1121.
   PubMed Web of Science ®Google Scholar
• Zhigalova EA, Izosimova AI, Yuzhakova DV, et al. RNA-Seq-based TCR profiling reveals persistently increased intratumoral clonality in responders to anti-PD-1 therapy. Front Oncol. 2020;10:385.
   PubMed Web of Science ®Google Scholar
• Li B, Li T, Wang B, et al. Ultrasensitive detection of TCR hypervariable-region sequences in solid-tissue RNA-seq data. Nat Genet. 2017;49(4):482–483.
   PubMed Web of Science ®Google Scholar
• Levy E, Marty R, Garate Calderon V, et al. Immune DNA signature of T-cell infiltration in breast tumor exomes. Sci Rep. 2016;6:30064.
   PubMed Web of Science ®Google Scholar
• Tu YN, Tong WL, Samy MD, et al. Assessing microenvironment immunogenicity using tumor specimen exomes: Co-detection of TcR-alpha/beta V(D)J recombinations correlates with PD-1 expression. Int J Cancer. 2017;140(11):2568–2576.
   PubMed Web of Science ®Google Scholar
• Mai AT, Tong WL, Tu YN, et al. TcR-alpha recombinations in renal cell carcinoma exome files correlate with an intermediate level of T-cell exhaustion biomarkers. Int Immunol. 2018;30(1):35–40.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830 e814.
   PubMed Web of Science ®Google Scholar
• Raitakari M, Brown RD, Sze D, et al. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br J Haematol. 2000;110(1):203–209.
   PubMed Web of Science ®Google Scholar
• Zaman S, Chobrutskiy BI, Patel JS, et al. Antiviral T cell receptor complementarity determining region-3 sequences are associated with a worse cancer outcome: a pancancer analysis. Viral Immunol. 2020;33(5):404–412.
   PubMed Web of Science ®Google Scholar
• Fassas AB, Bolanos-Meade J, Buddharaju LN, et al. Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol. 2001;112(1):237–241.
   PubMed Web of Science ®Google Scholar
• Li G, Lewis RD, Mishra N, et al. A retrospective analysis of ten symptomatic multiple myeloma patients with HIV infection: a potential therapeutic effect of HAART in multiple myeloma. Leuk Res. 2014;38(9):1079–1084.
   PubMed Web of Science ®Google Scholar